A companion analysis on how microbiological hazards, supplements, and clinical nutrition are reshaping regulatory expectations

The recent $70 million verdict against Abbott Laboratories involving preterm infant formula and necrotizing enterocolitis (NEC) has focused attention on one product category. But the more important takeaway may lie beyond infant formula itself.

The case highlights a broader and increasingly important issue of how food and supplement products are evaluated when used by vulnerable populations.

The Bigger Question

The Abbott case raises a fundamental question for regulators, manufacturers, and courts alike – “What happens when products regulated as “food” carry high-consequence clinical risk?”

This is not limited to neonatal nutrition. It reflects a wider pattern across multiple product categories where the regulatory classification remains as a food or supplement but real-world use introduces elevated risk profiles and legal expectations increasingly reflect those risks.

Vulnerability-Driven Risk: The Underlying Pattern

The key driver is not simply clinical setting; it is who is exposed and what happens if the product fails. This concept of vulnerability-driven risk applies when consumer populations have reduced physiological resilience, outcomes of failure are severe (hospitalization, surgery, death) and exposure is frequent or unavoidable.

In these cases, even traditionally “low-risk” product categories can become high-consequence risk environments.

Where This Is Happening Today

Microbiological Contamination in Food Products

Foodborne pathogens such as Cronobacter sakazakii, Salmonella, and Listeria monocytogenes continue to pose serious risks. For the general population, these risks may be manageable. But for vulnerable individuals like infants, the elderly, and immunocompromised patients, the same hazard can result in severe illness or death.

Dietary Supplements with Bioactive Effects

Certain supplements contain ingredients that influence metabolism or cardiovascular function, interact with prescription medications, and produce drug-like physiological effects. Yet these products are regulated under a food-based framework, without premarket approval requirements.

In vulnerable users, this can lead to adverse events, regulatory scrutiny, and product liability exposure.

Specialized Nutrition and Medical Foods

Products such as infant formula, medical foods, and enteral nutrition are often used under medical supervision, essential to patient care, and administered to high-risk populations. But they continue to be regulated primarily as food.

When Regulation Meets Litigation

The Abbott case illustrates a critical point. In litigation, the focus shifts away from regulatory classification and toward risk and responsibility.

Courts evaluate whether harm was foreseeable in the affected population, whether controls were adequate for that level of risk, and whether warnings were clear and sufficient.

As a result, products regulated as food may be judged against expectations more typical of drugs or medical devices.

A Shift Toward Risk-Based Expectations

A broader trend is emerging where risk-based expectations are beginning to outweigh category-based regulatory frameworks. This shift is driven by real-world product use in vulnerable populations, increased visibility of adverse outcomes, and expanding litigation pressure.

Implications for Industry

Manufacturers across food, supplement, and clinical nutrition sectors should consider enhanced safety systems with more robust hazard analysis, expanded environmental monitoring, and stronger supply controls.

Risk communication should be more proactive, clearer, with more explicit labeling and improved communication pathways with clinicians and consumers. And evolving postmarket surveillance must include active signal detection, literature and adverse event monitoring, and a continuous reassessment of product safety.

And manufacturers should consider how a convergence with MedTech Practices may improve their safety systems. Especially in high-risk contexts where expectations may increasingly resemble those applied to regulated healthcare products.

MDP Perspective

The Abbott NEC litigation is not an isolated event; it is an indicator of a broader shift. Products used by vulnerable populations are being evaluated through a different lens, one that prioritizes real-world risk over regulatory category.

Manufacturers that recognize this shift early will be better positioned to anticipate regulatory and legal expectations, strengthen safety and quality systems. Both of which will better protect both patients and their organizations.

Conclusion

The Abbott case began as a dispute over infant formula. It may ultimately be remembered as part of a larger transformation of a movement toward vulnerability-driven expectations in the regulation and evaluation of food and supplement products.